Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s...
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME), société de biotechnologie de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes...
Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma’s CIR (€610k) as of September 30, 2024 Live broadcast of the General Meeting on...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.034 | 2.62345679012 | 1.296 | 1.33 | 1.222 | 23956 | 1.27414275 | DE |
4 | 0.108 | 8.8379705401 | 1.222 | 1.33 | 1.16 | 31292 | 1.24262019 | DE |
12 | 0.082 | 6.57051282051 | 1.248 | 1.5 | 1.16 | 53288 | 1.29240321 | DE |
26 | 0.09 | 7.25806451613 | 1.24 | 1.5 | 1.128 | 38270 | 1.28682933 | DE |
52 | 0.05 | 3.90625 | 1.28 | 1.5 | 0.91 | 48562 | 1.22039111 | DE |
156 | -1.495 | -52.9203539823 | 2.825 | 2.885 | 0.91 | 91730 | 1.70151553 | DE |
260 | 0.938 | 239.285714286 | 0.392 | 3.57 | 0.351 | 240919 | 1.43325326 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales